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Abstract
Background: Injection drug use provides an efficient mechanism for transmitting bloodborne viruses, including human
immunodeficiency virus (HIV) and hepatitis C virus (HCV). Effective targeting of resources for prevention of HIV and HCV
infection among persons who inject drugs (PWID) is based on knowledge of the population size and disparity in disease
burden among PWID. This study estimated the number of PWID in the United States to calculate rates of HIV and HCV
infection.
Methods: We conducted meta-analysis using data from 4 national probability surveys that measured lifetime (3 surveys) or
past-year (3 surveys) injection drug use to estimate the proportion of the United States population that has injected drugs.
We then applied these proportions to census data to produce population size estimates. To estimate the disease burden
among PWID by calculating rates of disease we used lifetime population size estimates of PWID as denominators and
estimates of HIV and HCV infection from national HIV surveillance and survey data, respectively, as numerators. We
calculated rates of HIV among PWID by gender-, age-, and race/ethnicity.
Results: Lifetime PWID comprised 2.6% (95% confidence interval: 1.8%–3.3%) of the U.S. population aged 13 years or older,
representing approximately 6,612,488 PWID (range: 4,583,188–8,641,788) in 2011. The population estimate of past-year
PWID was 0.30% (95% confidence interval: 0.19 %–0.41%) or 774,434 PWID (range: 494,605–1,054,263). Among lifetime
PWID, the 2011 HIV diagnosis rate was 55 per 100,000 PWID; the rate of persons living with a diagnosis of HIV infection in
2010 was 2,147 per 100,000 PWID; and the 2011 HCV infection rate was 43,126 per 100,000 PWID.
Conclusion: Estimates of the number of PWID and disease rates among PWID are important for program planning and
addressing health inequities.
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Introduction
Injection drug use provides an efficient mechanism for
transmitting bloodborne viruses, including human immunodefi-
ciency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus
(HBV). In the United States (U.S.), 8% of all new HIV infections
in 2010 were among persons who inject drugs (PWID) and 3%
were among PWID who also engaged in male-male sex [1]. In
2010, PWID comprised 22% of adults and adolescents living with
HIV infection in the United States [2]. PWID are estimated to
comprise about 16% of persons with acute HBV infection [3]. A
national probability survey, conducted from 1999 through 2002,
showed that 48% of adults aged 20–59 years who tested antibody
positive for HCV reported a history of injection drug use [4].
The disparity in disease burden among PWID compared to
their population size has been difficult to quantify. Although the
Centers for Disease Control and Prevention (CDC) routinely uses
population data from the Census Bureau to calculate disease rates
by selected demographic categories (e.g., sex, race/ethnicity, and
age at diagnosis) [3,5] no census data are available for the number
of PWID in the U.S. and rate calculations require this number for
the denominator. Rates allow for comparison among subgroups
and over time. Several methods have been used by various
countries to measure the size of populations of PWID, including:
1) the capture-recapture method, using data collected from the
population at risk; 2) the multiplier method, based on existing
data; and 3) the network scale-up method, based on data collected
from the general population [6]. For the U.S., multiple data
sources have been compiled to estimate the population size of
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PWID among the nation as a whole and for large metropolitan
areas [7–10]. While these estimates are informative, they are based
on past-year behavior, which is not the most relevant time period
for calculating disease rates from national HIV surveillance data,
which essentially measures lifetime behaviors [5], or for calculating
rates from national hepatitis C survey data since ever use of
injection drugs, even in the distant past, is a risk for HCV infection
[11].
Recently, CDC used meta-analysis to estimate the proportion of
the U.S. population who are men who have sex with men (MSM)
and quantify the burden of HIV and sexually transmitted diseases
among MSM [12]. Population size estimates together with census
and surveillance data were used to calculate disease rates among
MSM. Applying this established method, in this report we estimate
the population proportion of PWID and quantify the burden of
HIV and HCV infections among PWID. We conducted a meta-
analysis of national surveys to estimate the proportion of persons in
the U.S. who have injected drugs, used these estimates to calculate
disease metrics for PWID using national surveillance data for HIV
infection, and calculated rate ratios by gender, race/ethnicity, and
age. We used other methods to estimate rates of HIV infection
among PWID in Puerto Rico and rates of HCV infection among
adult PWID in the U.S. The estimates of the number of PWID
and rates of HIV and HCV infection among PWID are needed to
effectively plan, implement at an appropriate scale, and evaluate
programs that serve PWID with or at risk for bloodborne
infections such as HIV, HBV, or HCV.
Methods
Data Sources for Calculating the Proportion of PWID in
the U.S.
To identify data sources and methods for estimating the
population proportion of PWID in the United States, we
developed search strategies to identify relevant reports published
from 1993 through 2008 (see Checklist S1). The initial phase
(Phase 1) included an automated, systematic search of 5 electronic
databases (Medline, CINAHL, PsycInfo, Sociological Abstracts,
and Cochrane). We cross-referenced multiple search terms (i.e.,
keywords and each database’s index terms) in 3 domains: (1)
measurement descriptors (prevalence, epidemiologic methods,
measure, survey, assessment); (2) injection drug use (substance/
drug, use/abuse, intravenous/inject/parenteral); and (3) geogra-
phy (some or all of the U.S.). We kept search terms broad to avoid
overlooking any relevant references that might provide data or
different methods for estimating the PWID population proportion.
Two trained reviewers screened abstracts from each of the
2,695 unduplicated references for specific criteria. To avoid over-
estimation of population size, we excluded studies likely to have
disproportionately high proportions of PWID (e.g., studies among
HIV or HCV infected persons; studies focused on populations who
are mentally ill, incarcerated, or in drug treatment; and studies
that selected for PWID and non-PWID separately). We also
excluded school-based samples (including university students) as
these may under-estimate the PWID population proportion. We
included studies if they reported the proportion of PWID in the
sample. We screened conference abstracts and dissertations but
did not include them, as they provided too few details. A total of
2,702 abstracts met the key terms; 2,695 were excluded in first-
level screening. Full reports were obtained for the 7 abstracts that
met the Phase 1 selection criteria.
At this point we convened an expert consultation to provide
feedback on best methods for producing population estimates of
PWID for short-term use (i.e., based on available data) and for
longer-term use, which may require primary data collection. The
group of 10 experts represented persons who directed some of the
7 data systems identified in the Phase 1 automated search, those
who had calculated PWID population estimates, and researchers
studying PWID populations. For the short term, the expert
consultants endorsed the use of meta-analysis of national surveys
for making PWID population estimates, acknowledging the
limitations of these surveys. National household surveys have the
advantage of robust sampling methods and allow for population-
based inference; however, they are less robust for measurement of
injection drug use due to exclusions (people who are homeless or
institutionalized), stigma and social desirability influences related
to reporting injection drug use behavior, and small sample sizes of
PWID. The expert consultants recommended that we assess the
meta-analysis findings against other data sources that may not be
included in the meta-analysis.
For the second phase of study selection (Phase 2), we
incorporated input from the expert consultants and further
restricted our criteria. Studies were included if they were published
from 2000 through 2008 to reflect more recent data. Studies were
excluded if they provided inadequate description of methods or
were not ongoing national, population-based surveys. We restrict-
ed to ongoing surveys to allow for multiple years of data to provide
a more robust estimate of PWID. In addition, we manually
searched for national household surveys that measured injection
drug use and applied the Phase 2 selection criteria. Five reports
identified in Phase 1 were excluded and 2 national surveys were
included from the manual search for a total of 4 surveys used in
meta-analysis (Figure 1).
These 4 surveys were the National Survey of Family Growth
(NSFG, 2002 and 2006–2008), the National Survey of Drug Use
and Health (NSDUH, 2002–2009), the National Health and
Nutrition Examination Survey (NHANES, 1999–2008), and the
General Social Survey (GSS, 2000–2008). Relevant characteristics
of each survey—including website addresses for further informa-
tion about the sampling methods, human subjects review, response
rates, and weighting—are presented in Table 1. Notably, all
surveys were household-based probability samples and 3 of the 4
surveys used audio computer-assisted self-interview to collect
information on injection drug use.
For each survey we analyzed publicly available data using
SUDAAN software version 9.1 (RTI International, Research
Triangle Park, NC) [13] to account for the complex sample
designs. These surveys allowed for 2 estimates of the population
proportion of PWID based on recall period: an estimate for
‘‘lifetime’’ injection drug use and an estimate for ‘‘past year.’’ Due
to the small number of PWID in each survey year, we aggregated
data across years for more robust estimates, resulting in a single
estimate for each data source. Prior to aggregating, we examined
data for each year and determined no pattern of increasing or
decreasing trend during the 2000–2008 time period. Small sample
sizes and limited data points (surveys collected data every 2 years
or aggregated data into 2-year periods) may have limited power to
detect minor changes over time. However, the lack of trend in the
4 surveys is consistent with stable estimates of PWID reported by
Tempalski and colleagues for the period 1992–2007 [10]. For the
lifetime estimate, NSDUH, NHANES, and GSS contributed data;
for the past year estimate, NSDUH, NHANES, and NSFG
contributed data.
Meta-analysis for Estimating the Proportion of PWID in
the U.S.
To combine the distinct estimates into a summary measure, we
applied meta-analytic methods recently extended to survey data
HIV and HCV Rates among Persons Who Inject Drugs
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[14]. For each recall period (ever, past year) we first multiplied
each survey estimate by a weight inversely proportionate to its
variance, summed the weighted estimates across studies, and then
divided by the sum of the weights.
The studies included for the meta-analysis were sufficiently
homogeneous in terms of sampling methods, participants, and
outcomes to provide a meaningful summary measure. All were
national probability surveys designed to make inference to the
U.S. household-based population, and collected self-reported data
on injection drug use. Despite these similarities, it is possible that
differences in characteristics of the surveys, such as question
wording, could result in heterogeneity. We selected random effects
models for our analyses because the models assume the studies are
a random sample [15], a type of inference that fits the purpose of
our study. In our analysis, the measures of injection drug use are
not identical across surveys but rather have a distribution; the
summary estimate describes the average of the measures and the
confidence interval provides an indication of the spread of the
distribution of population proportion estimates of PWID. The
meta-analysis method developed by Rao et al [14] adds a between-
studies variance term in deriving an overall estimate. Heteroge-
neity of estimates across surveys is indicated with the Q statistic
[14] and Higgins’ I2 index [16]. The Q statistic follows a chi-
squared distribution and assesses whether observed differences in
results are compatible with chance alone. I2 describes the
percentage of the variability in effect estimates that is due to
heterogeneity rather than sampling error [17]. Values of the Q
statistic indicated that the between-studies variance term was a
statistically significant source of variability suggesting that the
effects being estimated in the different surveys were not identical.
We also conducted stratified analyses to further address sources of
heterogeneity across surveys.
Stratified analyses for the lifetime estimate were conducted by
estimating the population proportion of PWID by sex, race/
ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, and
other), age group (18–24 years, 25–34 years, 35–49 years, 50–64
years), and for males and females separately by race/ethnic group
and by age group. The age groups were determined by the
structure of the public use NSDUH data; we restricted all datasets
to include only persons aged 18–64 years for comparability.
Stratified estimates were for the ever recall period only as there
were too few subjects in many of the cells of the cross-classification
to produce stable past-year estimates.
We carried out all estimates per Rao’s method using Microsoft
Excel (2007) and verified them using SAS Version 9.2 (SAS
Institute, Cary, NC). We used the Comprehensive Meta-Analysis
software version 2 (Biostat, Englewood, NJ) [18], which incorpo-
rates assumptions appropriate for synthesizing results from
observational studies and clinical trials, to verify results and assess
Figure 1. Survey Selection Flowchart for Meta-Analysis.
doi:10.1371/journal.pone.0097596.g001
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comparable patterns in the data. The estimates from these
methods yielded identical results (data not shown).
Method for Estimating the Numbers of Lifetime PWID in
the U.S.
We multiplied our newly derived lifetime estimates of the
population proportion of PWID by the population estimate from
the Census Bureau for persons aged 13 years or older for the 50
states and District of Columbia [19] to obtain an estimated
number of PWID.
The population proportions of PWID in the age group 18–24
years were applied to the population aged 13–24 years and the
population proportions of PWID in the age group 50–64 years
were applied to the population aged 50 years or older. Because
smaller percentages of persons in both age groups (13–17 and 65
years or older) are less likely to have ever injected drugs than those
aged 18–24 years and 50–64 years, respectively [20], this may
result in an over-estimate of the number of PWID and thus an
under-estimate of the rates of HIV infection.




























Ever Have you ever, even once, taken any
drugs by injection with a needle (like
heroin, cocaine, amphetamines, or
steroids)? Do not include anything














1999–2008 ACASI Ever, Past
year
Ever (1999–2004): Have you ever
used a needle to take street drugs?
(2005–2008): Have you ever, even
once, used a needle to inject a drug
not prescribed by a doctor? Past
year: (1999–2004) In the past 12
months, how many days have you
used a needle to take street drugs?
(Days greater than 0 indicated
injection drug behavior); (2005–2008):
How long ago has it been since you
last used a needle to inject a drug not
prescribed by a doctor? (Time periods















ACASI Past year 2002: During the last 12 months, how
often have you taken nonprescription
drugs using a needle, that is, you took
them only for the experience or
feeling it caused? This includes
‘shooting up’ and ‘skin-popping.’
(Frequencies greater than ’never’
indicated injection drug behavior)
2006: During the last 12 months, how
often have you shot up or injected
drugs other than those prescribed for
you? By shooting up, we mean
anytime you might have used drugs
with a needle, by mainlining, skin-
popping, or muscling. (Frequencies
greater than ’never’ indicated
injection drug behavior)
National Survey











2002–2009 ACASI Ever, Past
year
Ever: Have you ever, even once, used
a needle to inject heroin? Past year:
How long has it been since you last
used a needle to inject heroin? (also
asked for a) cocaine, b)
methamphetamine, c) other
stimulants, and d) other drugs not
prescribed/took for the feeling or
experience. (1) Within the past 30
days; (2) More than 30 days ago but
within past 12 months; (3) More than
12 months ago
CAPI = Computer Assisted Personal Interview; ACASI = Audio Computer-Assisted Self Interview.
*Spanish GSS interviews began in 2006.
{The public dataset used in this analysis is limited to persons aged 20–69 years, and only those 20–59 answered drug use questions.
1GSS data are collected every two years.
"Between 1973 and 2002, NSFG data were collected in cycles. Since 2006, NSFG data are continuously collected. This analysis included data from Cycle 6 (2002) and
2006 through 2008.
doi:10.1371/journal.pone.0097596.t001
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Method for Calculating HIV Disease Rates and Rate Ratios
among PWID in the U.S.
We calculated HIV rates by dividing the estimated number of
cases among PWID (numerator) by the estimated number of
PWID (denominator). We calculated two types of HIV rates for
the U.S.: 1) diagnosis rates and 2) the rates of PWID living with
diagnosed HIV infection. Data sources for rate calculations are
shown in Table S1.
For the numerators, we used HIV case surveillance data from
all 50 states and the District of Columbia reported to CDC as of
June 2012 for adults and adolescents (age 13 years or older at
diagnosis) diagnosed with HIV infection in 2011 and for those
living with diagnosed HIV infection as of December 2010. The
Table 2. Estimated proportion of persons who injected drugs (PWID) in their lifetime, by survey and combined by meta-analysis,
United States.
Population Survey % PWID 95% Confidence Interval
Males
NSDUH 2.7 2.6 2.9
NHANES 3.3 2.7 3.9
GSS 4.9 4.2 5.6
Combined estimate 3.6 2.4 4.8
Females
NSDUH 1.3 1.2 1.4
NHANES 1.4 1.1 1.8
GSS 2.1 1.7 2.5
Combined estimate 1.6 1.1 2.0
Total
NSDUH 2.0 1.9 2.1
NHANES 2.3 2.0 2.7
GSS 3.4 3.0 3.8
Combined estimate* 2.6 1.8 3.3
*Q2 = 45.1, p,0.0001, I
2 = 95.6.
NSDUH = National Survey of Drug Use and Health (2002–2009); NHANES = National Health and Nutrition Examination Survey (1999–2008); GSS = General Social Survey
(2000 – 2008).
doi:10.1371/journal.pone.0097596.t002
Table 3. Estimated proportion of persons who injected drugs (PWID) in the past year, by survey and combined by meta-analysis,
United States.
Population Survey % PWID 95% Confidence Interval
Males
NHANES 0.42 0.26 0.66
NSDUH 0.30 0.26 0.35
NSFG 0.45 0.29 0.60
Combined estimate 0.36 0.26 0.47
Females
NHANES 0.26 0.15 0.46
NSDUH 0.14 0.12 0.16
NSFG 0.28 0.16 0.40
Combined estimate 0.21 0.10 0.32
Total
NHANES 0.34 0.24 0.48
NSDUH 0.22 0.19 0.25
NSFG 0.36 0.27 0.46
Combined estimate* 0.30 0.19 0.41
*Q2 = 11.7, p,0.01, I
2 = 82.9.
NSDUH = National Survey of Drug Use and Health (2002–2009); NHANES = National Health and Nutrition Examination Survey (1999–2008); NSFG = National Survey of
Family Growth (2002 and 2006–2008).
doi:10.1371/journal.pone.0097596.t003
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most recently available data were used for both rates; data on
persons living with diagnosed HIV infection lags one year behind
diagnosis data due to time needed to ascertain deaths [5].
For the denominators, we used the estimated number of lifetime
PWID. Denominators were calculated by multiplying census data
by the lifetime PWID population proportion derived from the
meta-analysis. Our choice to use the estimate based on lifetime
injection drug use behavior for calculating rates best corresponds
to the HIV surveillance definition, which is injection drug use
since 1977 [5]. We used 2011 and 2010 census data, respectively,
to determine the number of PWID for the HIV diagnosis rates and
rates of living with diagnosed HIV infection (Table S1).
We calculated rate ratios to directly compare rates by sex, race/
ethnicity, and age. Females, whites, and the youngest age group
(13–24 years) served as the reference groups, respectively.
Method for Calculating HIV Disease Rate among PWID in
Puerto Rico
None of the surveys in the meta-analysis included Puerto Rico
in their sampling frames. Because Puerto Rico has a considerable
number of HIV diagnoses reported each year and approximately
40% are among PWID [21], we derived a method to calculate
HIV rates among PWID in Puerto Rico. A report by Perez and
colleagues [22] from a household survey conducted during 2005–
2008 indicated that 1.5% of adults aged 21–64 years in Puerto
Rico had ever injected drugs (no standard error reported). To
calculate a rate, we used the 1.5% population proportion of PWID
in Puerto Rico, Puerto Rico population totals from census data
[16], and the estimated number of PWID living with diagnosed
HIV infection in Puerto Rico in 2010 from CDC’s HIV case
surveillance data [5]. (Table S1).
Method for Calculating HCV Disease Rate among PWID in
the U.S.
For national estimates of the prevalence of HCV infection,
CDC relies on data from NHANES, which includes both an
interview and HCV antibody testing of the respondent, allowing
for calculation of disease rates by identification of persons
reporting lifetime injection drug use among those who are anti-
HCV positive. We analyzed NHANES data from 2003–2010 for
persons aged 40–65 years. This age range captures a majority of
those who may have reported injection drug use and roughly
corresponds to the age group for which CDC recommends one-
time HCV testing without prior ascertainment of HCV infection
risk [11]. To calculate the denominator for the rate, the estimate
for the population proportion of PWID in the age group 50–64
years was applied to 2011 census data for persons aged 40–65
years (Table S1).
Results
Proportion of the Population and Number Estimated to
be PWID in the U.S.
Table 2 shows the estimated population proportion of lifetime
PWID overall and for males and females for each population-
based survey and the combined estimates from the meta-analysis.
The overall combined estimate for the ever recall period was 2.6%
(confidence interval [CI]: 1.8%–3.3%). As noted, Q statistics and
I2 indicated heterogeneity of results across the surveys (Q2 = 45.1,
P ,.0001, I2 = 95.6). The combined estimate for males was 3.6%
(CI: 2.4%–4.8%) and for females was 1.6% (95% CI: 1.1%–2.0%).
Applying these proportions to the U.S. population age 13 years or
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and adolescents ever injected drugs, with a range from 4,583,188
to 8,641,788 persons; using the sex-specific proportions an
estimated 4,532,348 males (range: 3,040,447–6,024,250) and
2,059,709 females (range: 1,513,969–2,605,450) ever injected
drugs.
The overall combined estimate for the past year recall period
was 0.30% (CI: 0.19%–0.41%) (Table 3). Q statistics and I2
indicate heterogeneity of results across these surveys (Q2 = 11.7, P
,.01, I2 = 82.9). The combined past-year estimate for males was
0.36% (CI: 0.26%–0.47%) and for females was 0.21% (CI:
0.10%–0.32%). Applying these proportions to the U.S. population
age 13 years or older for 2011, we estimate that approximately
774,434 adults and adolescents (range: 494,605–1,054,263)
injected drugs in the past year in the United States.
We calculated lifetime population proportion estimates for male
and female PWID by race/ethnicity and by age group (Table 4).
The population proportion of PWID was highest among white
males (3.8% [CI: 2.7%–4.9%]) and lowest among Hispanic/
Latino females (0.7%, [CI: 0.5%–1.0%]). The population propor-
tion of PWID increased with age among those aged 18–49 years.
HIV Disease Rates and Rate Ratios among PWID in the
U.S.
Rates of diagnosis of HIV infection among PWID and rates of
PWID living with a diagnosis of HIV infection are presented in
Tables 5 and 6. The rate of diagnosis of HIV infection for PWID
was 55 per 100,000 PWID (CI: 42–80); the rate of PWID living
with a diagnosis of HIV infection was 2,147 per 100,000 PWID
(CI: 1,643–3,098). The rates for males were lower than those for
females for both measures, but not significantly different.
The rate ratios illustrate disparities by race/ethnicity. Compar-
ing black male PWID to white male PWID, the estimated rate of
diagnoses of HIV infection was 7–29 times as high (Table S2) and
the estimated rate of living with a diagnosis of HIV infection was
9–38 times as high (Table S3); comparing Hispanic/Latino to
white male PWID, these rates were 4–17 and 5–20 times as high,
respectively (Tables S2 and S3). Comparing black female PWID to
white female PWID, the estimated rate of diagnosis of HIV
infection was 5–29 times as high (Table S2) and the estimated rate
of living with a diagnosis of HIV infection was 6–42 times as high
(Table S3); comparing Hispanic/Latino to white female PWID,
these rates were 3–8 and 4–12 times as high, respectively (Tables
S2 and S3). By age, the rate of PWID living with a diagnosis of
HIV was higher among older age groups than those 13–24 years
for males and for females (Table S2).
HIV Infection Rate among PWID in Puerto Rico
The method we used to estimate the rate of persons living with a
diagnosis of HIV infection among PWID in Puerto Rico in 2010
produced a rate of 14,494 per 100,000 PWID (or a prevalence of
14.5%).
HCV Infection Rate among PWID in the U.S.
The prevalence rate of HCV infection among PWID aged 40–
65 years was 43,126 per 100,000 PWID (CI: 34,024–58,875).
Discussion
Using data from national population-based U.S. surveys, we
estimated that persons who ever injected drugs comprised 2.6%
(CI: 1.8%–3.3%) of the U.S. population. This represents
approximately 6,612,488 million PWID (range: 4,583,188–
8,641,788) aged 13 years or older in 2011. Although PWID
comprise 3% or less of the U.S. population, they account for 22%
of all persons living with HIV infection [2]. Our estimates also
quantified the recognized disparity of HIV disease rates among
black and Hispanic/Latino male and female PWID when
compared with white male and female PWID.
The rates we calculated for living with a diagnosis of HIV
infection in 2010 represent approximately 2% among male PWID
and 3% among female PWID. In recent years, national HIV
Table 5. Diagnoses of HIV infection among persons who inject drugs (PWID), by sex- - United States, 2011.
No. of PWID cases* Rate** 95% CI Rate Ratio 95% CI
Males 2,220 49 37–73 0.7 0.4–1.3
Females 1,428 69 55–94 1.0 —
Total 3,648 55 42–80
Note. Data include persons age 13 years and older with a diagnosis of HIV infection regardless of stage of disease at diagnosis. CI = confidence interval.
* Number of cases diagnosed with HIV infection or living with HIV infection was statistically adjusted to account for reporting delays and missing risk factor information,
but not for incomplete reporting.
**Per 100,000 PWID.
doi:10.1371/journal.pone.0097596.t005
Table 6. Persons who inject drugs (PWID) living with HIV, by sex - United States, 2010.
No. of PWID cases* Rate** 95% CI Rate Ratio 95% CI
Males 86,515 1927 1450–2873 0.7 0.4–1.4
Females 54,214 2653 2098–3610 1.0 —
Total 140,729 2147 1643–3098
Note. Data include persons age 13 years and older with a diagnosis of HIV infection regardless of stage of disease at diagnosis.
* Number of cases diagnosed with HIV infection or living with HIV infection was statistically adjusted to account for reporting delays and missing risk factor information,
but not for incomplete reporting.
**Per 100,000 PWID.
doi:10.1371/journal.pone.0097596.t006
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seroprevalence data among PWID have originated primarily from
NHANES [23], which was a data source in our meta-analysis.
More recent data on HIV seroprevalence among past-year PWID
in 20 cities with high AIDS prevalence was 9%, with similar
patterns of higher prevalence among black and Hispanic/Latino
compared to white PWID [24]. However, those data on past-year
PWID are not directly comparable to our rates which were based
on lifetime PWID.
Our past year estimate represents about 774,434 PWID in 2011
(range: 494,605–1,054,263). Tempalski and colleagues found a
2007 population estimate for PWID of approximately 1,500,000
with minimum and maximum estimates of approximately
1,300,000 and 1,700,000 million [10]. In view of the differences
between our study and that by Tempalski and colleagues in terms
of methods (meta-analysis vs. multiplier methods), datasets
(national surveys vs. drug and HIV testing data), and time periods
(2000–2008 vs. 1992–2007), and the lack of an accepted gold
standard method for PWID population size estimates [6], it is
unclear whether our estimate represents under-estimation or the
Tempalski method represents over-estimation. The use of any
PWID population size estimate should be accompanied by
acknowledgement of the limitations of the methods and data
sources.
Our rate of adults and adolescents living with a diagnosis of
HIV infection among PWID in Puerto Rico (14%) is higher than
that published by Perez and colleagues (2.8% [CI 0.6%–12.4%])
[22]. The estimate of the population proportion of PWID in
Puerto Rico (1.5%), based on a single household survey, could be
an under-estimate. In addition, the investigators cautioned that the
small number of HIV-infected persons limited their ability to make
reliable prevalence estimates stratified by injection drug use [22].
Our HCV infection prevalence rate among PWID aged 40–65
years was 43,126 per 100,000 population, reflecting the substantial
impact of injection drug use on acquiring HCV infection. The
HCV infection prevalence we found (43.1%) was similar to a
previous NHANES estimate of 48% [4]; the higher NHANES
prevalence may be due to the inclusion of PWID in a broader age
range than our estimate. The prevalence estimate points to the
importance of national efforts to raise awareness of HCV testing
among persons who have injected drugs [25]. In an era of
improved treatment, it is also important that those who are
infected are linked to appropriate care [11]. CDC recommends
integrated prevention services for PWID, which address risk for
HIV and HCV infections and are expected to result in increased
access to services, improved timeliness of service delivery, and
increased effectiveness of prevention efforts [26].
Our results are subject to several limitations. While the study
designs are robust in the 4 national surveys, they are hampered by
small proportion of participants reporting injection drug use.
Because PWID are a small proportion of the general population,
obtaining adequate numbers to produce stable estimates is difficult
without very large sample sizes. This difficulty is exacerbated when
estimates are stratified by sex, age, or race/ethnicity. In addition,
the illicit nature of and stigma associated with injection drug use
may have resulted in under-reporting of this behavior; however
this bias should be mitigated in part by use of ACASI for most
surveys included in our analysis. A second limitation is coverage
bias. The surveys in the meta-analysis exclude individuals without
stable housing. Given that a high proportion of PWID are unstably
housed [27,28], they are likely underrepresented in our analysis.
This coverage bias would result in an under-estimate of the
population proportion of PWID and an over-estimate of disease
rates. A third limitation is the degree of heterogeneity among
surveys. Although all surveys are population-based, the sampling
methods, age range, and question wording vary across surveys. We
used random-effects models to account for variance beyond
sampling errors. As noted, the rates among those aged 13–24 years
and 50 years or older may be under-estimates given that the meta-
analysis was limited to those aged 18–64 years. Other limitations
are inherent from the surveillance data used in the rate
calculations [5]. The HCV infection data are subject to the
limitations of NHANES [4].
Given the potential factors affecting the data in the 4 surveys
and the surveillance data, the population estimate and disease
rates should be presented with acknowledgement of their
limitations and interpreted in the context of the confidence
intervals presented; wider confidence intervals for some groups
indicate less precision in the estimates. The estimation method
presented here (meta-analysis results of ongoing, national survey
data) represents one method, as our expert consultants recognized,
for estimating the size of the PWID population in the United
States. As more research is conducted to estimate population size
of groups at risk for HIV and HCV infection, we will consider
using different methods in the future, should they prove more
accurate or more tractable than meta-analysis of national survey
data. These methods include capture-recapture, using data
collected from the population at risk, and network scale-up
method based on data collected from the general population [6].
For purposes of determining whether there are better methods or
data sources for use in the future, our expert consultants
recommended small-scale feasibility studies of multiple estimation
methods in one geographic area to be able to compare estimates
generated by these different methods (e.g., national survey,
network scale-up, and capture-recapture). However, for the short
term, synthesizing national surveys was recommended by the
expert consultants, the approach we took in this paper.
Estimating the population proportion of PWID allowed
calculation of rates of HIV and HCV infection, which quantifies
the disproportionate impact among PWID nationally. Trends
from population-based surveys will be monitored as part of CDC’s
behavioral surveillance analyses and the meta-analysis can be
updated as new data emerge. For HIV infection, rates can be
calculated on an annual basis with the most recent surveillance
data. Other disease metrics can be used to calculate rates, such as
HIV incidence [1] or national HIV prevalence estimates [2],
which include persons with undiagnosed HIV infection. Because
we calculated past year as well as lifetime estimates, others can use
either, depending on which best fits their needs. However, our
estimates may not be well suited for calculating disease rates at the
state or local level as the population sizes of PWID vary across the
U.S. [10].
The best available data must be used to guide decision-making
for disease prevention. The estimate of the number of PWID
(lifetime and past year) in the U.S. and quantifying the burden of
disease and disparities among PWID can be particularly important
for planning and evaluating programs serving disproportionately
affected populations and addressing health inequities at the
national level. The estimate of the number of PWID in the U.S.
and resulting rates are important additions to cost effectiveness
and other data used to make critical decisions about resources for
prevention of HIV and HCV infections.
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